KALA BIO, Inc. — Director's Dealing 2019

Jun 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2019-06-05

Reporting Person: Shah Rajeev M. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-05	Stock Option (right to buy)	$5.35	A	21000	Acquired	2029-06-04	Common Stock (21000)	Direct

Footnotes

F1: This option was granted on June 5, 2019 and vests with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter.

F2: Pursuant to the terms of the RA Capital Healthcare Fund, L.P., net proceeds from the options are payable to RA Capital Management, LLC as an offset to management fees.